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Objective. To investigate the presence and clinical
significance of autoantibodies against the interferon-
inducible gene IFI16 in systemic sclerosis (SSc), sys-
temic lupus erythematosus (SLE), and other auto-
immune diseases.
Methods. Immunohistochemical analysis was
used to evaluate the expression of IFI16 in skin biopsy
specimens obtained from patients with SSc and patients
with SLE. Levels of antibodies against IFI16 in sera
from 82 patients with SSc and 100 patients with SLE
were determined by enzyme-linked immunosorbent as-
say. Other autoimmune diseases such as primary Sjo¨-
gren’s syndrome (SS), rheumatoid arthritis (RA),
chronic urticaria, and hepatitis C virus (HCV) infection
were also examined.
Results. Expression of IFI16 was greatly in-
creased and was ubiquitous in all layers of the epider-
mis and in the dermal inflammatory infiltrates of
lesional skin from both patients with SLE and patients
with SSc. Patients with SLE, those with primary SS, and
those with SSc exhibited significantly higher anti-IFI16
IgG antibody levels compared with normal controls (for
SLE, P < 0.002; for primary SS, P < 0.001; for SSc, P <
0.0005). Anti-IFI16 titers above the ninety-fifth percen-
tile for control subjects were observed in 26% of the
patients with SLE, 50% of those with primary SS, and
21% of those with SSc (28% of patients with limited
cutaneous SSc [lcSSc] versus 4% of patients with diffuse
cutaneous SSc [dcSSc]). In contrast, the prevalence of
anti-IFI16 was 4% in patients with RA, 5% in those with
chronic urticaria, and 13% in those with HCV infection.
Conclusion. The results of this study provide
evidence that an IFN-inducible gene, IFI16, may be
involved in the pathophysiologic mechanisms of connec-
tive tissue disorders such as SSc. Moreover, a strict
correlation with lcSSc was also demonstrated, thus
providing a novel tool in the differential diagnosis of
lcSSc from dcSSc.
A family of interferon (IFN)–inducible genes,
designated HIN-200 in humans and Ifi200 in murine
species, encodes evolutionarily related human proteins
(IFI16, IFIX, MNDA, and AIM-2) and mouse proteins
(p202, p203, p204, p205/D3) (1). The IFI16, p202, and
p204 nuclear phosphoproteins participate in the inhibi-
tion of cell cycle progression, the modulation of differ-
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entiation, and cell survival. Gene expression analyses in
congenic mice have identified Ifi202 as a candidate gene
for lupus susceptibility (2).
Anti-IFI16 antibodies were reported in 29% of
patients with systemic lupus erythematosus (SLE) (3)
and in up to 70% of both patients with primary Sjo¨gren’s
syndrome (SS) and those with secondary SS (4). A lower
prevalence (0–13%) was observed in patients with rheu-
matoid arthritis (RA) and in those with scleroderma
(systemic sclerosis; SSc)–polymyositis overlap syndrome
(3%) (3,4). However, the studies on SS and RA enrolled
small series of patients, and no data are available on the
presence of these autoantibodies in SSc. The first aim of
the current study was to evaluate the presence of
anti-IFI16 autoantibodies in a larger number of patients
with SS or RA as well as in patients with SSc and
controls, and to partially characterize their antigenic
specificity.
Moreover, the expression of IFI16 in target tissue
involved in the autoimmune process (i.e., the salivary
glands) has also been described (4). This finding raises
the possibility that local tissue expression (or even
up-regulation) can be pivotal in triggering an auto-
immune response against this protein. Interestingly,
physiologic expression of IFI16 was observed in vascular
endothelial cells and in stratified squamous epithelia
such as skin (5). Both of these tissues are targets for the
main clinical manifestations of SLE and SSc. Accord-
ingly, we evaluated the expression of IFI16 in lesional
skin samples obtained from patients with SLE and
patients with SSc, in order to investigate whether en-
hanced IFI16 expression might be associated with the
occurrence of autoantibodies.
PATIENTS AND METHODS
Patients and controls. The study group comprised 100
patients with SLE, 20 patients with primary SS, 82 patients
with SSc, 50 patients with RA, and 38 patients with chronic
urticaria. As controls, we investigated 80 sex- and age-matched
healthy blood donors and 80 patients with chronic hepatitis C
virus (HCV) infection. Informed consent was obtained from all
participants.
All patients with SSc (73 women and 9 men, mean age
57 years [range 21–80 years]) were classified as having limited
cutaneous SSc (lcSSc) or diffuse cutaneous SSc (dcSSc) ac-
cording to the classification system described by LeRoy et al
(6). Disease severity was assessed using the preliminary disease
severity scale described by Medsger et al (7). All of the patients
with SLE (93 women and 7 men; mean age 40 years [range
18–65 years]) fulfilled the American College of Rheumatology
(ACR; formerly, the American Rheumatism Association) re-
vised criteria for the classification of SLE (8). Among the
patients with SLE, 48% had kidney involvement, and 17% had
secondary antiphospholipid syndrome. Disease activity was
evaluated according to the European Consensus Lupus Activ-
ity Measure (9). Patients with RA (39 women and 11 men;
mean age 54 years [range 25–70 years]) fulfilled the ACR 1987
classification criteria for RA (10). Patients with primary SS (17
women and 3 men; mean age 48 years [range 27–64 years])
were classified according to the classification criteria described
by Vitali (11). Patients with chronic urticaria (29 women and 9
men; mean age 38 years [range 22–50 years]) were selected as
previously described (12).
Keratoconjunctivitis was evaluated by ophthalmo-
scopic evaluation, Schirmer’s test, tear break-up time, and rose
bengal staining. Keratoconjunctivitis was diagnosed in 26% of
patients with SSc, 10% of patients with SLE, 19% of patients
with RA, and 6% of patients with HCV infection.
Skin biopsy specimens from 6 patients with SSc (4 with
lcSSc and 2 with dcSSc) and from 8 patients with SLE, all of
which were obtained for diagnostic purposes during a period of
active skin disease, were available for immunohistochemical
analysis. Control biopsy samples were obtained from the
unaffected skin of patients undergoing surgery for unrelated
diseases.
Recombinant proteins. The entire coding sequence of
the b isoform of human IFI16 was subcloned in the pET30a
expression vector (Novagen, Madison, WI), containing an
N-terminal histidine tag. The sequences encoding the
N-terminal (IFI16 N-term [amino acid residues 1–205]) or
C-terminal (IFI16 C-term [amino acid residues 525–726])
fragments of IFI16 were amplified by polymerase chain reac-
tion and cloned in frame in the pET30a vector. Expression and
affinity purification were performed according to standard
procedures. The purity of the proteins was assessed by 10%
sodium dodecyl sulfate–polyacrylamide gel electrophoresis. As
negative controls for enzyme-linked immunosorbent assay
(ELISA) and immunoblotting, the polypeptide encoded by the
pET30a empty vector (control peptide) was expressed and
purified according to the same protocol.
Immunoblotting and immunohistology. Immunoblot-
ting for recombinant IFI16, IFI16 N-term, IFI16 C-term, or
control peptide (pET30a) was carried out as previously de-
scribed (13). Immunohistochemical analysis for IFI16 expres-
sion was performed on paraffin-embedded tissue sections, as
previously described (5).
Determination of antibody titers toward human re-
combinant IFI16, by ELISA. Polystyrene microwell plates
(Nunc-Immuno MaxiSorp; Nunc, Roskilde, Denmark) were
coated for 16 hours at 4°C with 2 g/ml of either recombinant
IFI16 or control peptide in phosphate buffered saline (PBS).
After blocking with 3% bovine serum albumin–PBS, sera
(1:100) were added in duplicate and incubated for 1 hour at
37°C. After washing, horseradish peroxidase–conjugated rab-
bit anti-human IgG (Dako Cytomation, Carpenteria, CA) was
added and incubated for 1 hour at 37°C. After the addition of
substrate, absorbance was measured at 490 nm, using a micro-
plate reader (Bio-Rad, Hercules, CA). The background reac-
tivity of the reference mixture was subtracted to calculate the
results. A standard curve was constructed by serially diluting
anti-IFI16–positive patient sera.
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Statistical analysis. Statistical analysis was performed
with SPSS software (SPSS, Chicago, IL), using one-way analy-
sis of variance (ANOVA) with Bonferroni adjustment for
multiple comparisons. Either Fisher’s exact test or the chi-
square test was used to measure association. The independent
effect of significant variables was assessed using forward
conditional logistic regression analysis. Positivity cutoff values
were calculated as the ninety-fifth percentiles for the control
population. In the event of substantial deviation from normal-
ity, data were natural log–transformed before parametric
analysis was performed.
RESULTS
Elevated levels of anti-IFI16 autoantibody by
ELISA, and IFI16 immunoreactivity in SSc and SLE
skin. In normal epidermis obtained from healthy control
subjects, the expression of IFI16 was restricted to the
basal layer (Figure 1A). Notably, the expression of IFI16
was greatly increased and was ubiquitous in all layers of
the epidermis in lesional skin from both patients with
SLE (Figure 1B) and those with SSc (either lcSSc or
dcSSc) (Figure 1C). Furthermore, the dermal inflamma-
tory infiltrate showed IFI16-positive staining, indicating
that IFI16 is expressed at a high level in lymphocytes,
fibroblasts, and endothelial cells.
The presence of anti-IFI16 autoantibodies in
both patient and control sera was assessed by ELISA.
All absorbance levels were in the range of assay linear-
ity. Values higher than the ninety-fifth percentile for
control subjects were considered positive. Patients with
SSc, patients with SLE, and patients with SS exhibited
significantly higher anti-IFI16 IgG antibody levels com-
pared with control subjects (for SSc, P  0.0005; for
SLE, P  0.002; for primary SS, P  0.001) (Figure 2).
In contrast, the prevalence of anti-IFI16 IgG was not
statistically significantly different in patients with RA,
patients with chronic urticaria, and those with HCV
infection, in comparison with normal control subjects.
Interestingly, although the mean anti-IFI16 autoanti-
body titer in the whole group of patients with HCV
infection was not statistically significantly different from
that in control subjects, the subgroup of patients who
received treatment with type I IFN (n  20) displayed
considerably higher levels (mean optical density [OD]
0.346) compared with the untreated subgroup (mean
OD 0.206). This finding indirectly supports a role for
type I IFN in the up-regulation of IFI16 expression and
the eventual generation of specific autoantibodies.
Association of anti-IFI16 antibodies with clinical
parameters. Univariate analysis showed that anti-IFI16
autoreactivity in patients with SSc was not associated
with the duration or severity of disease, organ involve-
ment, and positivity to other autoantibodies (data not
shown). In contrast, a strict association between anti-
IFI16 reactivity and the limited cutaneous form of SSc
Figure 1. Expression of IFI16 in A, the skin of a healthy control subject, B, lesional
skin from a patient with systemic lupus erythematosus, and C, lesional skin from a
patient with limited cutaneous systemic sclerosis (original magnification  10). D,
Higher-magnification view of C, showing IFI16 staining in inflammatory cells.
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was observed, with patients with lcSSc displaying higher
anti-IFI16 IgG titers compared with patients with dcSSc
(P  0.017). Indeed, anti-IFI16 titers above the ninety-
fifth percentile for control subjects were observed in
28% of patients with lcSSc but in only 4% of those with
dcSSc (95% confidence interval 5–37%) (Figure 2B).
Consistent with previous reports, the presence or
titers of anti-IFI16 antibodies did not correlate with
clinical manifestations or disease activity in either pa-
tients with SLE or those with primary SS (data not
shown).
Logistic regression model and sensitivity–
specificity analysis. Consistent with data in the litera-
ture, the prevalence of anticentromere antibodies
(ACAs) and the prevalence of anti–Scl-70 antibodies in
patients with lcSSc were 65% and 9%, respectively,
compared with 8% and 75%, respectively, in patients
with dcSSc. Logistic regression analysis showed that
anti–Scl-70 antibodies, ACAs, and anti-IFI16 antibodies
were independent predictors of the cutaneous form of
SSc, and their combination was able to explain 62% of
the associated variability. This model was able to cor-
rectly predict 89% of the clinical variants. Moreover,
anti-IFI16 reactivity displayed lower sensitivity (28%)
and higher specificity (96%) than were observed for
ACAs (65% and 92%, respectively). The combined use
of anti-IFI16 and ACA markers gave rise to the highest
sensitivity and specificity scores (79% and 92%, respec-
tively). Interestingly, in the subgroup of patients with
SSc who were negative for both ACAs and anti–Scl-70
antibodies (n  24), all those with anti-IFI16 positivity
(n  6) displayed the limited cutaneous form (100%
specificity and 100% positive predictive value). None of
these patients presented with an overlap syndrome or
were positive for anti-RNP autoantibodies, and kerato-
conjunctivitis sicca was observed in 3 of these 6 patients.
No association was observed between anti-IFI16 anti-
bodies and keratoconjunctivitis sicca in patients with SSc
or in those with SLE, RA, or HCV infection.
Immunoblot analysis for anti-IFI16 antibodies.
Immunoblot analysis using recombinant IFI16 protein,
either full-length or deleted fragments (Figure 3A), was
also performed. Western blotting was performed on 25
SSc sera, 17 of which had anti-IFI16 titers above the
ninety-fifth percentile for control subjects and 8 of which
had titers below the ninety-fifth percentile for control
subjects. Low-titer sera did not exhibit reactivity with
IFI16, thus confirming specificity of the ELISA tech-
nique (Figure 3B). In contrast, only 10 of 17 sera with
high titers of IFI16 were positive, very likely because of
the ability of immunoblotting to detect antibodies
against linear epitopes, while ELISA recognizes autoanti-
bodies against both linear and conformational epitopes. A
correlation between anti-IFI16 autoantibody titers and the
intensity of immunoreactive bands was not observed.
To further characterize the antigenic specificity
of the IFI16-positive sera, 10 sera recognizing linear
epitopes were analyzed for their reactivity against the
N-terminal (IFI16 N-term) and C-terminal (IFI16
C-term) fragments of IFI16, respectively. Four sera
displayed reactivity against the N-terminal fragment, 3
sera displayed reactivity against the C-terminal frag-
ment, 2 sera recognized both fragments, and 1 serum
sample displayed no reaction (Figure 3C). Taken to-
gether, these data suggest a polyclonal nature of the
immune response against IFI16 in patients with SSc.
DISCUSSION
To our knowledge, this is the first demonstration
(by immunohistochemical analysis) of enhanced expres-
sion of IFN-inducible protein IFI16 in the epidermis and
Figure 2. IgG titers against human recombinant IFI16 in A, patients
with systemic sclerosis (SSc) (n  82), systemic lupus erythematosus
(SLE) (n  100), primary Sjo¨gren’s syndrome (SjS) (n  20),
rheumatoid arthritis (RA) (n  50), chronic urticaria (CU) (n  38),
and hepatitis C virus (HCV) infection (n  80), and healthy control
subjects (n  80), and B, patients with limited cutaneous SSc (lcSSc)
(n  57) and diffuse cutaneous SSc (dcSSc) (n  25), and healthy
control subjects (n  80). Data are presented as box plots. Each box
represents the 25th to 75th percentiles. Lines outside the boxes
represent the 10th and the 90th percentiles. Lines inside the boxes
represent the median. Circles indicate outliers. Differences between
the groups were evaluated by one-way analysis of variance with
Bonferroni adjustment for multiple comparisons, after logarithmic
transformation. Values beneath the boxes represent the percentage of
subjects with IgG titers above the cutoff value (0.360), calculated as the
95th percentile for the control population. OD  optical density.  
P 0.002 versus controls in A;  P 0.02 versus patients with dcSSc
and controls in B.
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dermal inflammatory infiltrate from both SLE and SSc
lesions. Additionally, we confirmed that anti-IFI16 au-
toantibody titers are significantly elevated in patients
with SLE and those with primary SS. Interestingly, we
observed that the prevalence of these autoantibodies
was comparable in SSc as well. The results obtained
demonstrated that anti-IFI16 autoreactivity was not
associated with either disease duration or disease sever-
ity but was associated with the limited cutaneous form of
SSc.
The most striking data came from logistic regres-
sion analysis of the 3 serologic markers of autoimmunity
(anti-IFI16 antibodies, ACAs, and anti–Scl-70 autoanti-
bodies). We actually observed that all 3 serologic mark-
ers were independent predictors of the cutaneous sub-
sets of SSc, and their combination was able to explain
62% of the associated variability. Although we failed to
detect an association with specific clinical features, their
presence seems to be an important clue to the develop-
ment of lcSSc in ACA- and anti–Scl-70–negative pa-
tients. In addition, the finding that anti-IFI16 positivity
distinguishes patients with lcSSc from among the sub-
group of patients negative for both ACA and anti–Scl-70
reactivity strongly indicates that anti-IFI16 can be a
useful diagnostic tool.
Prominent expression of IFI16 has been observed
in endothelial cells and in stratified squamous epithelia
such as skin. Its expression normally is restricted to the
basal proliferative layer, suggesting a possible role in the
control of skin homeostasis. Transduction of IFI16 into
human umbilical vein endothelial cells by recombinant
viruses efficiently suppressed the formation of capillary-
like structures in vitro and cell cycle progression associ-
ated with cell death (14). In the current study, we
Figure 3. A, Schematic representation of IFI16 and a series of recombinant IFI16
fragments. Domain a and domain b of HIN-200 are shown. Boxed areas indicate
recombinant peptides corresponding to IFI16 amino acids 1–205 (IFI16 N-term) and amino
acids 525–726 (IFI16 C-term), respectively. B, Immunoblot analysis showing reactivity with
full-length IFI16. Recombinant IFI16 or control peptide (pET30a) was separated by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis, transferred to nitrocellulose mem-
branes, and then incubated with a 1:100 dilution of patient serum that was positive (lanes
1–12, with decreasing titers) or negative (lanes 13 and 14) using enzyme-linked immunosor-
bent assay (ELISA). C, Reactivity with IFI16 N-terminal (IFI16 N-term) and C-terminal
(IFI16 C-term) fragments or control peptide (pET30a). Nitrocellulose membranes with
transferred recombinant proteins were incubated with patient sera that were reactive (by
immunoblotting) with full-length IFI16. After stripping, the membranes in B and C were
reprobed with anti-IFI16 C-terminal or anti-IFI16 N-terminal antibodies to confirm the
presence of the recombinant proteins.
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showed that IFI16 is expressed to a higher level in SSc
(regardless of the clinical subset) and SLE lesions in
both epithelial and inflammatory cells, and autoantibody
titers against it are significantly elevated in both dis-
eases. However, because the number of skin biopsy
specimens available was low and corresponding sera
were not available for all of them, we cannot make any
statistical correlation between anti-IFI16 antibodies and
the abnormal expression of IFI16 in skin.
Thus, the disease model we propose is as follows:
1) IFI16 expression in lesional skin may be enhanced by
local production of type I IFN or by other proinflamma-
tory stimuli; 2) IFI16 release, as a consequence of
increased cell death, leads to the breakdown in tolerance
to this self antigen, as confirmed by the generation of
specific anti-IFI16 autoantibodies; 3) an additional
pathogenic role of IFI16 is suggested by the observation
that its endothelial expression triggers apoptosis, up-
regulates the expression of genes encoding adhesion
molecules (intercellular adhesion molecule 1,
E-selectin) and chemokines (interleukin-8, monocyte
chemotactic protein 1) (Landolfo S: unpublished obser-
vations), and efficiently suppresses formation of
capillary-like structures in vitro.
Because the etiopathogenesis of SLE, primary
SS, and SSc is multifactorial, we can only speculate that
such events can be shared in common and that addi-
tional and completely different downstream mechanisms
may be responsible for the (clinical/histologic) differ-
ences between these diseases. Alternatively, regardless
of the cause of overexpression of IFI16, increased
exposure of the protein to immune effectors prone to
autoimmunity—such as in SLE, primary SS, and SSc—
may explain the production of specific autoantibodies.
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